Search
aplaviroc (GW873140, AK-602)
Investigational agent, 2005
Indications:
- HIV
- used in combination with Combivir (AZT/3TC) or Kaletra (lopinavir/ritonavir)
Dosage: 200-800 mg PO BID
Adverse effects:
- hepatotoxicity (severe hepatotoxity 0.5-1%) (clinical trials stopped over concerns of severe hepatotoxicity, 2005)
Mechanism of action:
- CCR5 antagonist
General
antiviral agent
Database Correlations
PUBCHEM cid=3001322
References
http://aids-clinical-care.jwatch.org/cgi/content/full/2005/928/1